https://doi.org/10.55788/bf33fea2
Dr Richard Hansen (University of Dundee, UK) and his team performed a systematic review on diet and nutrition in IBD, for which they screened 11,470 abstracts and included 659 papers. A total of 74 statements were adopted in the ECCO consensus paper. “General recommendations included that patients with IBD should have access to a dietitian who has experience with IBD and that people with IBD should adopt a diet that is in line with healthy eating guidelines,” said Dr Hansen [1]. “I would also like to highlight that the diet to reduce the risk for IBD is very different from the diet that is used as induction or maintenance therapy in patients with IBD.”
Five working groups developed statements for various topics within the scope of IBD management. Dr Hansen and Dr Vaios Svolos (University of Thessaly, Greece) presented a selection of these statements.
- Svolos V and Hansen R. ECCO consensus on diet and nutrition in IBD. SCI17, 20th Congress of ECCO, 19–22 February 2025, Berlin, Germany.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« ECCO Topical Review: pouch-related disorders Next Article
Identifying patients at high risk for chronic pouchitis »
« ECCO Topical Review: pouch-related disorders Next Article
Identifying patients at high risk for chronic pouchitis »
Table of Contents: ECCO 2025
Featured articles
Novelties and Future Prospects in IBD
Antibody responses predict IBD onset 10 years before diagnosis
Therapeutic antibody clearance reliable predictor for endoscopic outcomes in CD
Higher neoplasia detection rate with virtual chromoendoscopy in real-world IBD study
Reducing the carbon footprint of IBD care
Emerging Treatment Options in IBD
TL1A-LTB axis induces perianal fistulising disease-associated changes in CD
Emulsifier-restrictive diet effective in alleviating symptoms in CD
Could stem cell transplantation be a fruitful solution for refractory CD?
First IL-7 inhibitor for UC shows its potential
Novel TL1A inhibitor achieves high rates at stringent endpoints in UC
Positive results for TL1A inhibitor duvakitug in CD
New Data from Established Agents
Improving efficacy with longer mirikizumab treatment in CD
Long-term upadacitinib data reassuring for patients with UC
EFFICACI: Infliximab or vedolizumab after TNF failure in UC?
Latest data for subcutaneous guselkumab in CD and UC
Long-term use of etrasimod in UC safe and well-tolerated
Sustained efficacy and stable safety profile for risankizumab in UC
VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD
More News from ECCO 2025
PREdiCCT: Role of psychosocial factors in IBD flares unravelled
Kono-S or side-to-side anastomosis for resection in Crohn’s terminal ileitis?
Identifying patients at high risk for chronic pouchitis
ECCO consensus on diet and nutrition in IBD
ECCO Topical Review: pouch-related disorders
Related Articles
October 23, 2019
Locally active corticosteroid promising in eosinophilic oesophagitis
September 25, 2020
Obesity rising among hospitalized Crohn’s patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com

